ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $12.50 Average Target Price from Brokerages

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $12.50.

ALXO has been the subject of several research reports. UBS Group lowered their price objective on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a report on Tuesday, November 12th. Stifel Nicolaus restated a “hold” rating and set a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research report on Tuesday, August 13th.

Hedge Funds Weigh In On ALX Oncology

Several institutional investors have recently bought and sold shares of ALXO. Barclays PLC boosted its position in ALX Oncology by 243.6% during the 3rd quarter. Barclays PLC now owns 59,502 shares of the company’s stock valued at $107,000 after acquiring an additional 42,185 shares in the last quarter. XTX Topco Ltd bought a new stake in ALX Oncology during the third quarter valued at about $578,000. Wellington Management Group LLP grew its stake in ALX Oncology by 15.2% in the third quarter. Wellington Management Group LLP now owns 167,831 shares of the company’s stock valued at $305,000 after purchasing an additional 22,114 shares during the last quarter. Verition Fund Management LLC raised its holdings in ALX Oncology by 308.4% in the third quarter. Verition Fund Management LLC now owns 133,025 shares of the company’s stock worth $242,000 after purchasing an additional 100,454 shares in the last quarter. Finally, Walleye Capital LLC lifted its position in shares of ALX Oncology by 110.3% during the third quarter. Walleye Capital LLC now owns 230,875 shares of the company’s stock valued at $420,000 after buying an additional 121,113 shares during the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Stock Down 2.0 %

NASDAQ:ALXO opened at $1.48 on Thursday. The stock has a fifty day simple moving average of $1.54 and a 200-day simple moving average of $4.45. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a market cap of $78.06 million, a price-to-earnings ratio of -0.50 and a beta of 1.03. ALX Oncology has a twelve month low of $1.19 and a twelve month high of $17.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.